Multiple myeloma involving testes and bones

Abstract

Multiple myeloma (MM) remains the third most common hematological malignancy -its global incidence averages 1.78 cases per 100 000, but in some regions (that is, in norther Europe) is almost twice as high (3.82 / 100 000) [1,2]. Solitary plasmacytoma accounts for less than 5% of plasma cell dyscrasias. Half of plasmacytomas are located within the bones

Plasma cell myeloma as one of the causes of bone pain in family medicine

“…the mechanisms leading to hypercalcemia associated with malignant tumors are divided into three categories: humoral hypercalcemia caused by secreted factors (such as PthrP, i.e., parathy-roid hormone-related protein, or inflammatory cytokines), local osteolysis due to tumor invasion or humoral factors (only in case of impaired kidney function) and absorptive hypercalcemia due to excess vitamin D produced by cancer cells [2,3].…”

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone

“…Therefore, despite improvements in survival rates, multiple myeloma continues to pose a significant burden on the healthcare system with respect to morbidity and deleterious effects on health-related quality of life (HRQoL) for patients living with an incurable cancer [2][3][4].…”